The short answer
Ask the prescriber managing tranylcypromine before taking an L-tyrosine supplement, and avoid self-directed co-use. This search did not establish a direct clinical interaction for the exact pair. The concern comes from related MAOI precautions; a retracted phenelzine review cannot establish safety.
What this answer covers
Oral L-tyrosine supplements with tranylcypromine tablets. Tyrosine is not tyramine, and neither ordinary protein foods nor other amino acids are automatically included.
- Supplement or preparation
- L-Tyrosine
- Medication ingredient
- tranylcypromine
What the exact label says
Tranylcypromine has strict restrictions on sympathomimetic products. The inspected label does not name L-tyrosine individually. A phenelzine label does, but that is evidence about a different medication and must be identified as such.
Tyrosine is not tyramine
The names are similar, but a tyrosine supplement is not the same exposure as tyramine in food. The tyramine-food warning alone does not establish an exact tyrosine interaction or justify indiscriminate protein restrictions.
Why an apparently reassuring review was excluded
A phenelzine-tyrosine review was retracted after key supporting studies were retracted. It cannot be used to clear this combination. Removing unreliable reassurance still does not create direct evidence of a tranylcypromine event.
The practical next step
Have the intended product and reason for use reviewed before starting it. No safe co-use dose or spacing interval was established in this search. Do not alter tranylcypromine treatment yourself.
Evidence and practical considerations
Side effects & toxicity
The PARNATE label prohibits sympathomimetic supplements but does not individually name tyrosine. NARDIL, a different MAOI, explicitly names L-tyrosine. Applying that precaution across drugs is an inference, not a verified exact-pair clinical finding.
- Exact scope
- Oral L-tyrosine supplements with tranylcypromine tablets. Tyrosine is not tyramine, and neither ordinary protein foods nor other amino acids are automatically included. with Oral tranylcypromine tablets; current sulfate-tablet labeling uses the named active ingredient.
- Medication form and route
- oral
What remains uncertain
- No exact tranylcypromine-L-tyrosine clinical trial or usable direct case was identified. The other-drug label cannot be represented as a PARNATE-specific contraindication.
Factors that may matter: Exact supplement preparation and complete concomitant-medication list require assessment..
Read the supporting source summaries
Source 1: Current U.S. prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral tranylcypromine sulfate tablets.
The label contraindicates sympathomimetic supplements, hydroxytryptophan, tryptophan and SAM-e; it names St. John's wort in the serotonin-syndrome warning and lists excessive caffeine among exposures to avoid.
How this applies: Primary authority for exact tranylcypromine tablet precautions. Named supplements and class-based applications are kept distinct.
A labeled contraindication is not a measurement of the frequency of an event with each product; L-tyrosine and Panax ginseng are not individually named.
Source 2: Current U.S. prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral phenelzine sulfate tablets.
The label prohibits sympathomimetics, L-tryptophan, L-tyrosine, phenylalanine and serotonergic agents. It warns about excessive caffeine and high-tyramine exposures.
How this applies: Different MAOI labeling, used only to identify a class inference or contrast. It is not the current medication's label.
Regulatory instructions do not quantify an exact-pair event rate or validate every botanical formulation.
Source 3: Publisher retraction notice
tandfonline.com · Source check Sep 10, 2026
Population: No clinical participants; publication-integrity notice.
The publisher retracted the review because its central arguments relied on original research articles that had also been retracted.
How this applies: This is a reason to exclude that review, not clinical evidence that the combination causes harm or is safe.
This is a reason to exclude that review, not clinical evidence that the combination causes harm or is safe.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial targeted research draft. Inspected source material, adjudicated the current checker statements, and recorded preparation limits. Clinical review has not occurred. | |
| Research summary published |
Article revision: 3980ee55690f4baa
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.